267 related articles for article (PubMed ID: 18855532)
1. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Lane HY; Lee CC; Liu YC; Chang WH
Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
[TBL] [Abstract][Full Text] [Related]
3. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.
Wei Z; Wang L; Xuan J; Che R; Du J; Qin S; Xing Y; Gu B; Yang L; Li H; Li J; Feng G; He L; Xing Q
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):547-51. PubMed ID: 19233240
[TBL] [Abstract][Full Text] [Related]
4. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
5. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
[TBL] [Abstract][Full Text] [Related]
6. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
[TBL] [Abstract][Full Text] [Related]
7. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
[TBL] [Abstract][Full Text] [Related]
8. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.
Ma L; Zhang X; Xiang Q; Zhou S; Zhao N; Xie Q; Zhao X; Zhou Y; Cui Y
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):94-104. PubMed ID: 30103286
[TBL] [Abstract][Full Text] [Related]
9. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
[TBL] [Abstract][Full Text] [Related]
10. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
[TBL] [Abstract][Full Text] [Related]
11. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
12. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment.
Cai HL; Fang PF; Li HD; Zhang XH; Hu L; Yang W; Ye HS
Psychiatry Res; 2011 Jul; 188(2):197-202. PubMed ID: 21146875
[TBL] [Abstract][Full Text] [Related]
13. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Kim B; Choi EY; Kim CY; Song K; Joo YH
Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
[TBL] [Abstract][Full Text] [Related]
14.
Grubor M; Zivkovic M; Sagud M; Nikolac Perkovic M; Mihaljevic-Peles A; Pivac N; Muck-Seler D; Svob Strac D
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32231051
[TBL] [Abstract][Full Text] [Related]
15. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
[TBL] [Abstract][Full Text] [Related]
16. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.
Zhang A; Xing Q; Wang L; Du J; Yu L; Lin Z; Li X; Feng G; He L
Pharmacogenomics; 2007 Oct; 8(10):1337-45. PubMed ID: 17979508
[TBL] [Abstract][Full Text] [Related]
18. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
19. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
[TBL] [Abstract][Full Text] [Related]
20. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
[Next] [New Search]
